Belite Bio announces $15 million direct offering to new healthcare investor

From GlobeNewswire: 2025-02-05 22:35:00

Belite Bio, Inc. has entered into a securities purchase agreement with a new healthcare investor for the sale of 258,309 ADSs and warrants, generating approximately $15 million in gross proceeds. The Company intends to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on February 7, 2025, subject to customary closing conditions and is being conducted under a shelf registration statement on Form F-3. Belite Bio focuses on developing therapeutics for degenerative retinal diseases. Forward-looking statements included in the press release caution on completion of the offering and potential risks.



Read more at GlobeNewswire: Belite Bio Announces Registered Direct Offering of $15